Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Aspyron Inc is development stage company that will be completing preparations for ...
Aspyron Inc is development stage company that w...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Orthogonal is a Socially Conscious Holding Company. As such, we only invest in co...
Orthogonal is a Socially Conscious Holding Comp...
At Bellerophon Therapeutics, we aim to transform the lives of people suffering fro...
At Bellerophon Therapeutics, we aim to transfor...
Horizon is a biopharmaceutical company focused on researching, developing and comm...
Horizon is a biopharmaceutical company focused ...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Join the National Investor Network and get the latest information with your interests in mind.